IMMUNOVANT INC. - CO
13.62
14-May-25 11:19:37
15 minutes delayed
Stocks
-0.40
-2.85%
Today's range
13.62 - 14.11
ISIN
N/A
Source
NASDAQ
-
Immunovant to Host Virtual R&D Day on March 30, 2022
28 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
09 Feb 2022 08:00:01 By Nasdaq GlobeNewswire
-
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
04 Feb 2022 07:00:00 By Nasdaq GlobeNewswire
-
Immunovant Appoints Mark Levine as Chief Legal Officer
25 Jan 2022 08:30:00 By Nasdaq GlobeNewswire
-
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
07 Jan 2022 14:07:31 By Nasdaq GlobeNewswire
-
30 Dec 2021 07:00:00 By Nasdaq GlobeNewswire
-
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
12 Nov 2021 12:18:05 By Nasdaq GlobeNewswire
-
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
05 Nov 2021 07:30:00 By Nasdaq GlobeNewswire
-
Immunovant to Participate in Roivant R&D Day 2021
27 Sep 2021 08:00:00 By Nasdaq GlobeNewswire
-
Immunovant Appoints Renee Barnett as Chief Financial Officer
15 Sep 2021 07:00:01 By Nasdaq GlobeNewswire
-
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
09 Aug 2021 06:30:00 By Nasdaq GlobeNewswire
-
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
06 Aug 2021 16:22:27 By Nasdaq GlobeNewswire
-
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
02 Aug 2021 07:30:00 By Nasdaq GlobeNewswire
-
01 Jun 2021 07:31:18 By Nasdaq GlobeNewswire
-
Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020
16 Feb 2021 08:00:04 By Nasdaq GlobeNewswire
-
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
02 Feb 2021 06:30:00 By Nasdaq GlobeNewswire
-
Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
12 Jan 2021 17:00:00 By Nasdaq GlobeNewswire